FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma.

Abstract

Fludarabine (FLU) is a new antimetabolite chemotherapeutic agent with promising therapeutic activity in the lymphoproliferative disorders and in particular in low-grade non-Hodgkin's lymphoma (LG-NHL). In order to evaluate FLU in combination with other antineoplastic agents, we used a three-drug combination of FLU, mitoxantrone and prednisone (FMP) to treat 18 patients with recurrent LG-NHL. The FMP regimen was as follows: FLU, 25 mg/m2 i.v. on days 1 to 3; mitoxantrone, 10 mg/m2 i.v. on day 1; prednisone 40 mg i.v. on days 1 to 5. Of the 18 patients, 4 (22%) achieved complete response (CR), 9 (50%) partial response, and the remaining 5 showed no benefit from the treatment. The 4 CR patients are still in remission after 4, 6, 6, and 8 months, respectively. The median duration of overall survival of all patients was 9 months. The major toxic effects observed were neutropenia (50%) and infections and/or febrile episodes (17%); no fatalities due to drug side effects occurred. These results confirm the efficacy of the fludarabine-mitoxantrone combination-containing regimen in inducting a good remission rate with moderate side effects in recurrent LG-NHL.

• Authors: P L Zinzani, M Bendandi, S Tura
• Journal: European journal of haematology (Eur J Haematol) Vol. 55 Issue 4 Pg. 262-6 (Oct 1995) ISSN: 0902-4441 [Print] England
• PMID: 7589345 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Antineoplastic Agents
• Mitoxantrone
• Vidarabine
• fludarabine
• Prednisone

Topics

• Adult
• Antineoplastic Agents (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use, toxicity)
• Drug Administration Schedule
• Female
• Humans
• Lymphoma, Non-Hodgkin (drug therapy, pathology)
• Male
• Middle Aged
• Mitoxantrone (administration & dosage)
• Neoplasm Staging
• Prednisone (administration & dosage)
• Recurrence
• Vidarabine (administration & dosage, analogs & derivatives)